Heterocyclic modulators of lipid synthesis
US-2024400552-A1 · Dec 5, 2024 · US
Compound with α-glucosidase inhibitory activity and application thereof
US12448390B1 · US · B1
| Field | Value |
|---|---|
| Publication number | US-12448390-B1 |
| Application number | US-202519031233-A |
| Country | US |
| Kind code | B1 |
| Filing date | Jan 17, 2025 |
| Priority date | Jul 31, 2024 |
| Publication date | Oct 21, 2025 |
| Grant date | Oct 21, 2025 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
The present invention belongs to the technical field of chemical drugs, and specifically to a compound with a-glucosidase inhibitory activity and application thereof. 5-hydroxymethyl-8-methyl-2-(N-arylamino)-pyrano[2,3-c]pyridine-3-(N-aryl)-formamide series compound is provided, possessing a structure in General formula (I). Compared with compounds with anti-diabetes activity in general sense, the compound with the strong anti-diabetes activity of the present disclosure has the apparently more important application value.
First claim
Opening claim text (preview).
The invention claimed is: 1. A compound with a-glucosidase inhibitory activity having a structure shown in General formula (I) below: wherein R1 is halogen, R2 is a C1-C2 alcoholic hydroxyl. 2. A pharmaceutical composition for treating diabetes, wherein the pharmaceutical composition comprises the compound according to claim 1 and a pharmaceutically acceptable carrier. 3. A method for treating diabetes comprising administering a compound according to claim 1 to a patient in need thereof.
Assignees
Inventors
Classifications
Ortho-condensed systems · CPC title
the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin · CPC title
- C07D491/052Primary
the oxygen-containing ring being six-membered · CPC title
for hyperglycaemia, e.g. antidiabetics · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US12448390B1 cover?
- The present invention belongs to the technical field of chemical drugs, and specifically to a compound with a-glucosidase inhibitory activity and application thereof. 5-hydroxymethyl-8-methyl-2-(N-arylamino)-pyrano[2,3-c]pyridine-3-(N-aryl)-formamide series compound is provided, possessing a structure in General formula (I). Compared with compounds with anti-diabetes activity in general sense, …
- Who is the assignee on this patent?
- Univ China Agricultural
- What technology area does this patent fall under?
- Primary CPC classification C07D491/052. Mapped technology areas include Chemistry & Metallurgy.
- When was this patent published?
- Publication date Tue Oct 21 2025 00:00:00 GMT+0000 (Coordinated Universal Time) (B1). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).